ISTA Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye in the United States. The company offers Xibrom for the treatment of inflammation and pain following cataract surgery; Istalol for the treatment of glaucoma; and Vitrase for use as a spreading agent. Its developing products include Bepotastine ophthalmic solution for allergic conjunctivitis; T-Pred, a Phase III clinical trial product candidate for the treatment of steroid-responsive inflammatory ocular conditions; Ecabet Sodium, a Phase IIb clinical trial product, for the treatment of dry eye syndrome; and Bepotastine nasal for the treatment of allergic rhinitis. The company?s products developing products also include a steroid product candidate to treat ocular inflammation; iganidipine to enhance ocular nerve blood flow; and a formulation of latanoprost for the treatment of glaucoma. It sells its products primarily to drug wholesalers, retailers, and distributors, including chain drug stores, hospitals, clinics, government agencies, and managed healthcare providers. ISTA Pharmaceuticals was formerly known as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in March 2000. The company was founded in 1992 and is headquartered in Irvine, California VALUATION MEASURES Market Cap (intraday)5: 74.11M Enterprise Value (10-May-09)3: 91.87M Trailing P/E (ttm, intraday): N/A Forward P/E (fye 31-Dec-10) 1: 13.18 PEG Ratio (5 yr expected): N/A Price/Sales (ttm): 1.01 Price/Book (mrq): N/A Enterprise Value/Revenue (ttm)3: 1.11 Enterprise Value/EBITDA (ttm)3: -3.866 FINANCIAL HIGHLIGHTS Fiscal Year Fiscal Year Ends: 31-Dec Most Recent Quarter (mrq): 31-Dec-08 Profitability Profit Margin (ttm): -36.92% Operating Margin (ttm): -29.86% Management Effectiveness Return on Assets (ttm): -20.09% Return on Equity (ttm): N/A Income Statement Revenue (ttm): 83.08M Revenue Per Share (ttm): 2.515 Qtrly Revenue Growth (yoy): 46.70% Gross Profit (ttm): 61.13M EBITDA (ttm): -23.76M Net Income Avl to Common (ttm): -30.67M Diluted EPS (ttm): -0.93 Qtrly Earnings Growth (yoy): N/A Balance Sheet Total Cash (mrq): 53.02M Total Cash Per Share (mrq): 1.602 Total Debt (mrq): 70.77M Total Debt/Equity (mrq): N/A Current Ratio (mrq): 1.765 Book Value Per Share (mrq): -0.52 Cash Flow Statement Operating Cash Flow (ttm): -22.50M Levered Free Cash Flow (ttm): -16.24M TRADING INFORMATION Stock Price History Beta: 0.34 52-Week Change3: 40.00% S&P500 52-Week Change3: -33.07% 52-Week High (08-May-09)3: 2.60 52-Week Low (11-Nov-08)3: 0.29 50-Day Moving Average3: 1.94 200-Day Moving Average3: 1.26 Share Statistics Average Volume (3 month)3: 101,890 Average Volume (10 day)3: 225,456 Shares Outstanding5: 33.09M Float: 17.97M % Held by Insiders1: 23.86% % Held by Institutions1: 58.70% Shares Short (as of 09-Apr-09)3: 100.62K Short Ratio (as of 09-Apr-09)3: 5 Short % of Float (as of 09-Apr-09)3: 0.30% Shares Short (prior month)3: 99.14K Dividends & Splits Forward Annual Dividend Rate4: N/A Forward Annual Dividend Yield4: N/A Trailing Annual Dividend Rate3: N/A Trailing Annual Dividend Yield3: NaN% 5 Year Average Dividend Yield4: N/A Payout Ratio4: N/A Dividend Date3: N/A Ex-Dividend Date4: N/A Last Split Factor (new per old)2: 1:10 Last Split Date3: 14-Nov-02
$2.24 (05/10/09)
